Dmitry Balyasny’s Dianthus Therapeutics DNTH Stock Holding History

Dmitry Balyasny’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8M	Sell	162,005 -312,080	-66%	-$27.3M	0.02%	834
2026 Q1	$39.8M	Buy	+474,085	New	+$27.5M	0.05%	419
2025 Q4	–	Sell	-443,703	Closed	-$17.5M	–	3191
2025 Q3	$17.5M	Buy	+443,703	New	+$11.3M	0.02%	776
2024 Q2	–	Sell	-13,371	Closed	-$401K	–	2683
2024 Q1	$401K	Buy	+13,371	New	+$291K	﹤0.01%	2140
2022 Q4	–	Sell	-761	Closed	-$17K	–	2875
2022 Q3	$17K	Buy	+761	New	+$20.8K	﹤0.01%	2596

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Dmitry Balyasny's DNTH Position: Q2 2026 in Review

Dmitry Balyasny reduced its Dianthus Therapeutics (DNTH) stake by 66% in Q2 2026, selling an estimated $27.3M and leaving 162,005 shares worth $15.8M. The position accounts for 0.02% of the portfolio, ranked #834.

Dmitry Balyasny first reported a position in DNTH in Q3 2022 and has held it in 5 quarters since. The position peaked at $39.8M in Q1 2026. 267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Dmitry Balyasny held 162,005 shares of Dianthus Therapeutics worth $15.8M as of Q2 2026.
Dmitry Balyasny sold 312,080 Dianthus Therapeutics shares in Q2 2026, an estimated $27.3M.
Dianthus Therapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #834 holding.
Dmitry Balyasny first reported a position in Dianthus Therapeutics in Q3 2022 and has held it in 5 quarters since.
Dmitry Balyasny's Dianthus Therapeutics position peaked at $39.8M in Q1 2026.
267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.